157 related articles for article (PubMed ID: 9335511)
1. The taxoids: same roots, different drugs.
Von Hoff DD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-3-S13-10. PubMed ID: 9335511
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
D'Andrea GM; Seidman AD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
[TBL] [Abstract][Full Text] [Related]
3. Docetaxel.
Leahy M; Howell A
Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel: a review of its pharmacology and clinical activity.
Trudeau ME
Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
[TBL] [Abstract][Full Text] [Related]
5. Future perspectives of docetaxel (Taxotere) in front-line therapy.
Piccart MJ; Di Leo A
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-27-S10-33. PubMed ID: 9275004
[TBL] [Abstract][Full Text] [Related]
6. The scientific rationale for developing taxoids.
Aapro M
Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
[TBL] [Abstract][Full Text] [Related]
7. The taxoids. Comparative clinical pharmacology and therapeutic potential.
Eisenhauer EA; Vermorken JB
Drugs; 1998 Jan; 55(1):5-30. PubMed ID: 9463787
[TBL] [Abstract][Full Text] [Related]
8. Docetaxel (Taxotere) in combination: a step forward.
Burris HA; Fields S; Peacock N
Semin Oncol; 1995 Dec; 22(6 Suppl 13):35-40. PubMed ID: 8604452
[TBL] [Abstract][Full Text] [Related]
9. Recent progress in the clinical development of docetaxel (Taxotere).
Hortobagyi GN
Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
Valero V
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
[TBL] [Abstract][Full Text] [Related]
11. Risks and benefits of taxanes in breast and ovarian cancer.
Michaud LB; Valero V; Hortobagyi G
Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
[TBL] [Abstract][Full Text] [Related]
12. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
13. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere).
Pazdur R; Kudelka AP; Kavanagh JJ; Cohen PR; Raber MN
Cancer Treat Rev; 1993 Oct; 19(4):351-86. PubMed ID: 8106152
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
15. Taxoids: a new class of cytotoxic agents.
Marty M; Extra JM; Giacchetti S; Cuvier C; Espie M
Nouv Rev Fr Hematol (1978); 1994; 36 Suppl 1():S25-8. PubMed ID: 7909941
[TBL] [Abstract][Full Text] [Related]
16. The clinical rationale for developing docetaxel (Taxotere).
Armand JP
Anticancer Drugs; 1996 Aug; 7 Suppl 2():37-9. PubMed ID: 8862710
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients resistant to paclitaxel therapy.
Valero V
Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
20. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]